Literature DB >> 33713012

A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.

Nidhi Doshi1, Jamie Giddings2, Lin Luis2, Arthur Wu2, Kyle Ritchie2, Wenqiang Liu2, Wayman Chan3, Rosalynn Taing2, Jeff Chu3, Alavattam Sreedhara2, Aadithya Kannan2, Pervina Kei2, Ian Shieh2, Tobias Graf4, Mark Hu2.   

Abstract

PURPOSE: Enzymatic polysorbate (PS) degradation and resulting free fatty acid (FFA) particles are detrimental to biopharmaceutical drug product (DP) stability. Different types and grades of polysorbate have varying propensity to form FFA particles. This work evaluates the homogenous all-oleate (AO) PS80 alongside heterogeneous PS20 and PS80 grades in terms its propensity to form FFA particles and other important attributes like interfacial protection and oxidation susceptibility.
METHODS: FFA particle formation rates were compared by degrading PS using non-immobilized hydrolases and fast degrading DP formulations. Interfacial protection of monoclonal antibodies (mAbs) was assessed by agitation studies in saline using non-degraded and degraded PS. Several antioxidants were assessed for their ability to mitigate AO PS80 oxidation and subsequent mAb oxidation by a 40°C placebo stability study and a 2, 2'-Azobis (2-amidinopropane) dihydrochloride stress model, respectively.
RESULTS: Visible and subvisible particles were significantly delayed in AO PS80 formulations compared with heterogeneous PS20 and PS80 formulations. Non-degraded AO PS80 was less protective of mAbs against the air-water interface compared with heterogeneous PS20. Interfacial protection by AO PS80 improved upon degradation owing to high surface activity of FFAs. Diethylenetriaminepentaacetic acid (DTPA) completely mitigated AO PS80 oxidation unlike L-methionine and N-Acetyl-DL-Tryptophan. However, DTPA did not mitigate radical mediated mAb oxidation.
CONCLUSION: AO PS80 is a promising alternative to reduce FFA particle formation compared with other PS types and grades. However, limitations observed here---such as lower protection against interfacial stresses and higher propensity for oxidation---need to be considered in assessing the risk/benefit ratio in using AO PS80.

Entities:  

Keywords:  free fatty acids; monoclonal antibodies; polysorbate hydrolysis; polysorbate oxidation; visible particles

Year:  2021        PMID: 33713012     DOI: 10.1007/s11095-021-03021-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  49 in total

1.  Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.

Authors:  Nidhi Doshi; Joelle Martin; Anthony Tomlinson
Journal:  Mol Pharm       Date:  2020-10-08       Impact factor: 4.939

2.  Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions.

Authors:  N B Bam; J L Cleland; J Yang; M C Manning; J F Carpenter; R F Kelley; T W Randolph
Journal:  J Pharm Sci       Date:  1998-12       Impact factor: 3.534

3.  Analysis of polysorbate 80 and its related compounds by RP-HPLC with ELSD and MS detection.

Authors:  R Zhang; Y Wang; L Tan; H Y Zhang; M Yang
Journal:  J Chromatogr Sci       Date:  2012-04-26       Impact factor: 1.618

4.  Mixed-mode and reversed-phase liquid chromatography-tandem mass spectrometry methodologies to study composition and base hydrolysis of polysorbate 20 and 80.

Authors:  Daniel Hewitt; Melissa Alvarez; Kathryn Robinson; Junyan Ji; Y John Wang; Yung-Hsiang Kao; Taylor Zhang
Journal:  J Chromatogr A       Date:  2010-09-29       Impact factor: 4.759

Review 5.  Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.

Authors:  Bruce A Kerwin
Journal:  J Pharm Sci       Date:  2008-08       Impact factor: 3.534

6.  Adsorption behavior of a surfactant and a monoclonal antibody to sterilizing-grade filters.

Authors:  Hanns-Christian Mahler; Franziska Huber; Ravuri S K Kishore; Jürgen Reindl; Peter Rückert; Robert Müller
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

7.  Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh-performance liquid chromatography-charged aerosol detection-mass spectrometry.

Authors:  Yi Li; Daniel Hewitt; Yvonne K Lentz; Junyan A Ji; Taylor Y Zhang; Kelly Zhang
Journal:  Anal Chem       Date:  2014-05-02       Impact factor: 6.986

8.  Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations.

Authors:  Nidhi Doshi; Barthélemy Demeule; Sandeep Yadav
Journal:  Mol Pharm       Date:  2015-10-13       Impact factor: 4.939

9.  Behaviour of polysorbate 20 during dialysis, concentration and filtration using membrane separation techniques.

Authors:  Hanns-Christian Mahler; Miriam Printz; Robert Kopf; Rudolf Schuller; Robert Müller
Journal:  J Pharm Sci       Date:  2008-02       Impact factor: 3.534

Review 10.  Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes.

Authors:  Mridula Dwivedi; Michaela Blech; Ingo Presser; Patrick Garidel
Journal:  Int J Pharm       Date:  2018-10-06       Impact factor: 5.875

View more
  3 in total

1.  Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization.

Authors:  Ankit D Kanthe; Miriam R Carnovale; Joshua S Katz; Susan Jordan; Mary E Krause; Songyan Zheng; Andrew Ilott; William Ying; Wei Bu; Mrinal K Bera; Binhua Lin; Charles Maldarelli; Raymond S Tu
Journal:  Mol Pharm       Date:  2022-07-26       Impact factor: 5.364

2.  A Mechanistic Understanding of Monoclonal Antibody Interfacial Protection by Hydrolytically Degraded Polysorbate 20 and 80 under IV Bag Conditions.

Authors:  Aadithya Kannan; Jamie Giddings; Shrenik Mehta; Tiffany Lin; Anthony Tomlinson; Kyle Ritchie; Ian Shieh; Miguel Saggu; Nidhi Doshi
Journal:  Pharm Res       Date:  2022-03-11       Impact factor: 4.200

Review 3.  The measurement and control of high-risk host cell proteins for polysorbate degradation in biologics formulation.

Authors:  Xuanwen Li; Fengqiang Wang; Hong Li; Douglas D Richardson; David J Roush
Journal:  Antib Ther       Date:  2022-01-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.